Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now later-stage tilt small index

Harm Reduction: later-stage trial registry

6 of 8 indexed Harm Reduction trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 6 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Harm Reduction: 8 US clinical trials tracked, 6 recruiting.

Harm Reduction is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Nationwide Children's Hospital, running 1 of these trials.

Enrollment posture brief

Registry condition harm-reduction

OPEN 6 | RECR 75% | LATE 3 | EARLY 0 | RANK #2176 | SPON 1

Nearest open-share peer: Adolescent Idiopathic Scoliosis (75% recruiting · 8 trials)

Activity, Motor75%Harm Reduction (this)75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Harm Reduction

Harm Reduction lists 6 open slots (75% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Harm Reduction on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Harm Reduction is recruiting above its size-band peers.

    6 of 8 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Harm Reduction trials is spread across many organizations.

    Nationwide Children's Hospital accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Harm Reduction enrolment sits around 300 participants.

    Median target enrolment is 300 among the 8 trials that report a genuine target (sentinel values excluded). 2 of those (25%) plan for fewer than 100 participants.

  4. Harm Reduction research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 31Phase 42

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 2

Named interventions

Most-linked intervention names on Harm Reduction records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

HIV care Other
1 trials
Biktarvy 50Mg-200Mg-25Mg Tablet Drug
1 trials
Fentanyl Test Strips Behavioral
1 trials
Oral nicotine pouches Other
1 trials
E-cigarettes Other
1 trials
iDECIDE Behavioral
1 trials
VENDY Behavioral
1 trials
eHaRT-A Behavioral
1 trials

US sites by state

Facility locations filed on Harm Reduction trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
Washington 1 trials
Ohio 1 trials
New York 1 trials
Massachusetts 1 trials
Florida 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Harm Reduction page

8 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Harm Reduction condition card totals 8 registered trials; most-linked intervention HIV care; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.